KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $24.4 million.

  • CRISPR Therapeutics AG's Other Non-Current Assets rose 5394.53% to $24.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $24.4 million, marking a year-over-year increase of 5394.53%. This contributed to the annual value of $24.4 million for FY2025, which is 5394.53% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Other Non-Current Assets stood at $24.4 million, which was up 5394.53% from $24.3 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Other Non-Current Assets high stood at $25.5 million for Q2 2025, and its period low was $11.5 million during Q1 2024.
  • In the last 5 years, CRISPR Therapeutics AG's Other Non-Current Assets had a median value of $12.1 million in 2022 and averaged $15.4 million.
  • In the last 5 years, CRISPR Therapeutics AG's Other Non-Current Assets soared by 23414.01% in 2021 and then plummeted by 3291.46% in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Other Non-Current Assets stood at $16.9 million in 2021, then tumbled by 31.21% to $11.6 million in 2022, then decreased by 0.38% to $11.6 million in 2023, then soared by 36.56% to $15.8 million in 2024, then surged by 53.95% to $24.4 million in 2025.
  • Its Other Non-Current Assets was $24.4 million in Q4 2025, compared to $24.3 million in Q3 2025 and $25.5 million in Q2 2025.